Archer’s biochip development involves miniaturising medical lab tests onto an integrated circuit, a single chip, that is only a few millimetres in size. The chip includes a number of functional areas and componentry, including microfluidic channels and active biosensing areas – all smaller than the thickness of a human hair.
Miniaturising and integrating a lab-on-chip device also provides improved accuracy and a
substantial decrease in the time required to obtain a diagnostic test result, which are key
commercial barriers to point of care medical diagnostic disease testing. Specifically:
+ Archer’s biochip componentry and design solves for sample evaporation challenges and
substantially overcome limitations in fabricating the active sensing areas to meet
miniaturisation requirements for viable disease detection.
+ The biochip microfluidics allow sample sorting, preparation, and handling – all on-chip.
Sample volumes as small as 3 microlitres (“µL”) can be used – comparable to the volume
of a tear drop (6-7 µL) or blood droplet (50 µL) – which is more than 1000 times less than
the volume taken for a regular blood test (3-10 mL).
- Forums
- ASX - By Stock
- Ann: Access to institutional deep tech infrastructure expanded
Archer’s biochip development involves miniaturising medical lab...
Featured News
Add AXE (ASX) to my watchlist
(20min delay)
|
|||||
Last
21.5¢ |
Change
-0.005(2.27%) |
Mkt cap ! $54.79M |
Open | High | Low | Value | Volume |
22.5¢ | 22.5¢ | 21.5¢ | $69.64K | 316.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 119692 | 21.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
22.5¢ | 135450 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 115292 | 0.215 |
4 | 125500 | 0.210 |
12 | 140540 | 0.205 |
6 | 167238 | 0.200 |
2 | 50000 | 0.195 |
Price($) | Vol. | No. |
---|---|---|
0.225 | 134200 | 4 |
0.230 | 111314 | 3 |
0.235 | 12447 | 2 |
0.240 | 143397 | 3 |
0.245 | 20000 | 1 |
Last trade - 16.10pm 20/09/2024 (20 minute delay) ? |
Featured News
AXE (ASX) Chart |